Saturday, November 21, 2026

Zai Lab Stock Went Up By Over 9% So Far On Wednesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Zai Lab Stock Went Up By Over 9% So Far On Wednesday

Zai Lab is a NASDAQ-listed biotechnological firm founded in Shanghai with a focus on developing pharmaceutical treatments. The company has recently attracted attention as its shares rebounded by 9.55% to $47.50 after three consecutive days of losses on the NASDAQ. However, this rebound occurred despite a continuation of the downward trend from previous sessions, which saw another decline of 0.87%.

About Zai Lab

At the conclusion of its last trade, Zai Lab's shares stood at $43.19. This marked a significant 55.16% drop from its 52-week high of $96.95. Despite these market fluctuations, Zai Lab continues to develop a variety of products aimed at addressing an extensive range of health conditions. Their key focus areas include oncology, autoimmune disorders, infectious diseases, and neuroscience.

Product Range and Economic Health

Notable product offerings from Zai Lab include Zejula, Optune, NUZYRA, and Qinlock, with several other promising therapies currently in development. However, the company's economic stability seems unstable, evident by a trailing twelve-month earnings per share (EPS) figure of 4.32. Furthermore, a negative return on equity (ROE) percentage at 35.51% prompts questions about its profitability relative to shareholder equity.

Investment Outlook

Despite recent challenges, Zai Lab remains resilient with an estimated market cap of $47.50, comfortably more than its 52-week low of $33.98. As the pharmaceutical firm continues its R&D efforts to develop treatments for various diseases and conditions, its value could see significant changes. Investors are advised to stay aware of developments in the health sector, especially any occurring within Zai Lab, as they have the potential to greatly impact the company's share performance.

More news about Zai Lab (ZLAB).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 9 Aug 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.